|
1
|
Gao S, Qian X, Huang S, Deng W, Li Z and
Hu Y: Association between macronutrients intake distribution and
bone mineral density. Clin Nutr. 41:1689–1696. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Golshan M, Dortaj H, Rajabi M, Omidi Z,
Golshan M, Pourentezari M and Rajabi A: Animal origins free
products in cell culture media: A new frontier. Cytotechnology.
77:122025. View Article : Google Scholar
|
|
3
|
Hellmann A, Turyn J, Zwara A, Korczynska
J, Taciak A and Mika A: Alterations in the amino acid profile in
patients with papillary thyroid carcinoma with and without
Hashimoto's thyroiditis. Front Endocrinol (Lausanne).
14:11992912023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thompson R and Pickard BS: The amino acid
composition of a protein influences its expression. PLoS One.
19:e02842342024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li B, Roden DM and Capra JA: The 3D
mutational constraint on amino acid sites in the human proteome.
Nat Commun. 13:32732022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang Y, Fan C, Zhang Y, Kang T and Jiang
J: Untargeted metabolomics reveals the role of lipocalin-2 in the
pathological changes of lens and retina in diabetic mice. Invest
Ophthalmol Vis Sci. 65:192024.PubMed/NCBI
|
|
7
|
Zhu ZG, Ma JW, Ji DD, Li QQ, Diao XY and
Bao J: Mendelian randomization analysis identifies causal
associations between serum lipidomic profile, amino acid biomarkers
and sepsis. Heliyon. 10:e327792024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jin J, Meng T, Yu Y, Wu S, Jiao CC, Song
S, Li YX, Zhang Y, Zhao YY, Li X, et al: Human HDAC6 senses valine
abundancy to regulate DNA damage. Nature. 637:215–223. 2025.
View Article : Google Scholar
|
|
9
|
Scalise M, Console L, Rovella F, Galluccio
M, Pochini L and Indiveri C: Membrane transporters for amino acids
as players of cancer metabolic rewiring. Cells. 9:20282020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma Y, Han X, Fang J and Jiang H: Role of
dietary amino acids and microbial metabolites in the regulation of
pig intestinal health. Anim Nutr. 9:1–6. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Winkle LJ: Amino acid transport and
metabolism regulate early embryo development: Species differences,
clinical significance, and evolutionary implications. Cells.
10:31542021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grobben Y: Targeting amino
Acid-metabolizing enzymes for cancer immunotherapy. Front Immunol.
15:14402692024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu N, Shi F, Yang L, Liao W and Cao Y:
Oncogenic viral infection and amino acid metabolism in cancer
progression: Molecular insights and clinical implications. Biochim
Biophys Acta Rev Cancer. 1877:1887242022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fan Y, Xue H, Li Z, Huo M, Gao H and Guan
X: Exploiting the Achilles' heel of cancer: Disrupting glutamine
metabolism for effective cancer treatment. Front Pharmacol.
15:13455222024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu D, Zhang K, Khan FA, Pandupuspitasari
NS, Guan K, Sun F and Huang C: A comprehensive review on signaling
attributes of serine and serine metabolism in health and disease.
Int J Biol Macromol. 260:1296072024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kadivar D, Eslami Moghadam M and Notash B:
Effect of geometric isomerism on the anticancer property of new
platinum complexes with glycine derivatives as asymmetric N, O
donate ligands against human cancer. Spectrochim Acta A Mol Biomol
Spectrosc. 322:1248092024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kelly B and Pearce EL: Amino Assets: How
Amino Acids Support Immunity. Cell Metab. 32:154–175. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hushmandi K, Einollahi B, Saadat SH, Lee
EHC, Farani MR, Okina E, Huh YS, Nabavi N, Salimimoghadam S and
Kumar AP: Amino acid transporters within the solute carrier
superfamily: Underappreciated proteins and novel opportunities for
cancer therapy. Mol Metab. 84:1019522024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jakobsen S and Nielsen CU: Exploring amino
acid transporters as therapeutic targets for cancer: An examination
of inhibitor structures, selectivity issues, and discovery
approaches. Pharmaceutics. 16:1972024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang S, Lin X, Hou Q, Hu Z, Wang Y and
Wang Z: Regulation of mTORC1 by amino acids in mammalian cells: A
general picture of recent advances. Anim Nutr. 7:1009–1023. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gold LT and Masson GR: GCN2: Roles in
tumour development and progression. Biochem Soc Trans. 50:737–745.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang H, Kang R, Liu J and Tang D: ATF4 in
cellular stress, ferroptosis, and cancer. Archi Toxicol.
98:1025–1041. 2024. View Article : Google Scholar
|
|
23
|
Jiang C, Dai X, He S, Zhou H, Fang L, Guo
J, Liu S, Zhang T, Pan W and Yu H: Ring domains are essential for
GATOR2-dependent mTORC1 activation. Mol Cell. 83:74–89.e9. 2023.
View Article : Google Scholar
|
|
24
|
Berdenis van Berlekom A, Kübler R,
Hoogeboom JW, Vonk D, Sluijs JA, Pasterkamp RJ, Middeldorp J,
Kraneveld AD, Garssen J, Kahn RS, et al: Exposure to the amino
acids histidine, lysine, and threonine reduces mTOR activity and
affects neurodevelopment in a human cerebral organoid model.
Nutrients. 14:21752022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kumar M, Sahoo SS, Jamaluddin MFB and
Tanwar PS: Loss of liver kinase B1 in human seminoma. Front Oncol.
13:10811102023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yue S, Li G, He S and Li T: The central
role of mTORC1 in amino acid sensing. Cancer Res. 82:2964–2974.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaizuka T, Hara T, Oshiro N, Kikkawa U,
Yonezawa K, Takehana K, Iemura S, Natsume T and Mizushima N: Tti1
and Tel2 are critical factors in mammalian target of rapamycin
complex assembly. J Biol Chem. 285:20109–20116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu C, Pan X, Wang D, Guan Y, Yang W, Chen
X and Liu Y: O-GlcNAcylation of Raptor transduces glucose signals
to mTORC1. Mol Cell. 83:3027–3040.e11. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jie H, Wei J, Li Z, Yi M, Qian X, Li Y,
Liu C, Li C, Wang L, Deng P, et al: Serine starvation suppresses
the progression of esophageal cancer by regulating the synthesis of
purine nucleotides and NADPH. Cancer Metab. 13:102025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fu Y, Fu Z, Su Z, Li L, Yang Y, Tan Y,
Xiang Y, Shi Y, Xie S, Sun L and Peng G: mLST8 is essential for
coronavirus replication and regulates its replication through the
mTORC1 pathway. mBio. 14:e00899232023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma K, Xian W, Liu H, Shu R, Ge J, Luo ZQ,
Liu X and Qiu J: Bacterial ubiquitin ligases hijack the host
deubiquitinase OTUB1 to inhibit MTORC1 signaling and promote
autophagy. Autophagy. 20:1968–1983. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang C and Jiang D: Exogenous PRAS40
reduces KLF4 expression and alleviates hypertrophic scar fibrosis
and collagen deposition through inhibiting mTORC1. Burns.
50:936–946. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ye Q, Zhou W, Xu S, Que Q, Zhan Q, Zhang
L, Zheng S, Ling S and Xu X: Ubiquitin-specific protease 22
promotes tumorigenesis and progression by an
FKBP12/mTORC1/autophagy positive feedback loop in hepatocellular
carcinoma. MedComm (2020). 4:e4392023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fernandes SA, Angelidaki DD, Nüchel J, Pan
J, Gollwitzer P, Elkis Y, Artoni F, Wilhelm S, Kovacevic-Sarmiento
M and Demetriades C: Spatial and functional separation of mTORC1
signalling in response to different amino acid sources. Nat Cell
Biol. 26:1918–1933. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Meng D, Yang Q, Melick CH, Park BC, Hsieh
TS, Curukovic A, Jeong MH, Zhang J, James NG and Jewell JL: ArfGAP1
inhibits mTORC1 lysosomal localization and activation. EMBO J.
40:e1064122021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Daigh LH, Saha D, Rosenthal DL, Ferrick KR
and Meyer T: Uncoupling of mTORC1 from E2F activity maintains DNA
damage and senescence. Nat Commun. 15:91812024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Condon KJ, Orozco JM, Adelmann CH,
Spinelli JB, van der Helm PW, Roberts JM, Kunchok T and Sabatini
DM: Genome-wide CRISPR screens reveal multitiered mechanisms
through which mTORC1 senses mitochondrial dysfunction. Proc Natl
Acad Sci USA. 118:e20221201182021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang C, Tan X, Liu N, Yan P, Hou T and
Wei W: Nutrient sensing of mTORC1 signaling in cancer and aging.
Semin Cancer Biol. 106-107:1–12. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu M, Teng F, Li N, Zhang L, Zhang S, Xu
F, Shao J, Sun H and Zhu H: Monomethyl branched-chain fatty acid
mediates amino acid sensing upstream of mTORC1. Dev Cell.
56:31712021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yao Y, Hong S, Yoshida S, Swaroop V,
Curtin B and Inoki K: The Cullin3-Rbx1-KLHL9 E3 ubiquitin ligase
complex ubiquitinates Rheb and supports amino Acid-induced mTORC1
activation. Cell Rep. 44:1151012025. View Article : Google Scholar :
|
|
41
|
Hartung J, Müller C and Calkhoven CF: The
dual role of the TSC complex in cancer. Trends Mol Med. 31:452–465.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wan ZY, Tian JS, Tan HW, Chow AL, Sim AY,
Ban KH and Long YC: Mechanistic target of rapamycin complex 1 is an
essential mediator of metabolic and mitogenic effects of fibroblast
growth factor 19 in hepatoma cells. Hepatology. 64:1289–1301. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Feng Y, Li T, Li Y, Lin Z, Han X, Pei X,
Zhang Y, Li F, Yang J, Shao D and Li C: Glutaredoxin-1 promotes
lymphangioleiomyomatosis progression through inhibiting
Bim-mediated apoptosis via COX2/PGE2/ERK pathway. Clin Transl Med.
13:e13332023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Deng L, Chen L, Zhao L, Xu Y, Peng X, Wang
X, Ding L, Jin J, Teng H, Wang Y, et al: Ubiquitination of Rheb
governs growth factor-induced mTORC1 activation. Cell Res.
29:136–150. 2019. View Article : Google Scholar :
|
|
45
|
Crosby P, Hamnett R, Putker M, Hoyle NP,
Reed M, Karam CJ, Maywood ES, Stangherlin A, Chesham JE, Hayter EA,
et al: Insulin/IGF-1 drives PERIOD synthesis to entrain circadian
rhythms with feeding time. Cell. 177:896–909.e20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu L, Xiao B, Hirukawa A, Smith HW, Zuo
D, Sanguin-Gendreau V, McCaffrey L, Nam AJ and Muller WJ: Ezh2
promotes mammary tumor initiation through epigenetic regulation of
the Wnt and mTORC1 signaling pathways. Proc Natl Acad Sci USA.
120:e23030101202023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shi H, Chapman NM, Wen J, Guy C, Long L,
Dhungana Y, Rankin S, Pelletier S, Vogel P, Wang H, et al: Amino
acids license kinase mTORC1 activity and treg cell function via
small G proteins rag and rheb. Immunity. 51:1012–1027.e7. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sancak Y, Peterson TR, Shaul YD, Lindquist
RA, Thoreen CC, Bar-Peled L and Sabatini DM: The Rag GTPases bind
raptor and mediate amino acid signaling to mTORC1. Science.
320:1496–1501. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim E, Goraksha-Hicks P, Li L, Neufeld TP
and Guan KL: Regulation of TORC1 by Rag GTPases in nutrient
response. Nat Cell Biol. 10:935–945. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rogala KB, Gu X, Kedir JF, Abu-Remaileh M,
Bianchi LF, Bottino AMS, Dueholm R, Niehaus A, Overwijn D, Fils AP,
et al: Structural basis for the docking of mTORC1 on the lysosomal
surface. Science. 366:468–475. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Anandapadamanaban M, Masson GR, Perisic O,
Berndt A, Kaufman J, Johnson CM, Santhanam B, Rogala KB, Sabatini
DM and Williams RL: Architecture of human Rag GTPase heterodimers
and their complex with mTORC1. Science. 366:203–210. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Doxsey DD, Tettoni SD, Egri SB and Shen K:
Redundant electrostatic interactions between GATOR1 and the Rag
GTPase heterodimer drive efficient amino acid sensing in human
cells. J Biol Chem. 299:1048802023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Egri SB, Ouch C, Chou HT, Yu Z, Song K, Xu
C and Shen K: Cryo-EM structures of the human GATOR1-Rag-Ragulator
complex reveal a spatial-constraint regulated GAP mechanism. Mol
Cell. 82:1836–1849.e5. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sanders SS, De Simone FI and Thomas GM:
mTORC1 signaling is Palmitoylation-dependent in hippocampal neurons
and Non-neuronal cells and involves dynamic palmitoylation of
LAMTOR1 and mTOR. Front Cell Neurosci. 13:1152019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Laufenberg LJ, Crowell KT and Lang CH:
Alcohol acutely antagonizes Refeeding-induced alterations in the
Rag GTPase-ragulator complex in skeletal muscle. Nutrients.
13:12362021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cheng J, Lou Y and Jiang K: Downregulation
of long non-coding RNA LINC00460 inhibits the proliferation,
migration and invasion, and promotes apoptosis of pancreatic cancer
cells via modulation of the miR-320b/ARF1 axis. Bioengineered.
12:96–107. 2021. View Article : Google Scholar
|
|
57
|
Li FL and Guan KL: The Arf family GTPases:
Regulation of vesicle biogenesis and beyond. BioEssays: News and
reviews in molecular, cellular and developmental Biology.
45:e22002142023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fan SJ, Snell C, Turley H, Li JL,
McCormick R, Perera SM, Heublein S, Kazi S, Azad A, Wilson C, et
al: PAT4 levels control amino-acid sensitivity of
rapamycin-resistant mTORC1 from the Golgi and affect clinical
outcome in colorectal cancer. Oncogene. 35:3004–3015. 2016.
View Article : Google Scholar :
|
|
59
|
Huang T, Chen B, Wang F, Cai W, Wang X,
Huang B, Liu F, Jiang B and Zhang Y: Rab1A promotes
IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor
sensitivity in non-small cell lung cancer. Cancer Lett.
523:182–194. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Xu H, Qian M, Zhao B, Wu C, Maskey N, Song
H, Li D, Song J, Hua K and Fang L: Inhibition of RAB1A suppresses
epithelial-mesenchymal transition and proliferation of
triple-negative breast cancer cells. Oncol Rep. 37:1619–1626. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhao T, Fan J, Abu-Zaid A, Burley SK and
Zheng XFS: Nuclear mTOR signaling orchestrates transcriptional
programs underlying cellular growth and metabolism. Cells.
13:7812024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wolfson RL and Sabatini DM: The dawn of
the age of amino acid sensors for the mTORC1 pathway. Cell.
26:301–309. 2017.
|
|
63
|
Talaia G, Bentley-DeSousa A and Ferguson
SM: Lysosomal TBK1 responds to amino acid availability to relieve
Rab7-dependent mTORC1 inhibition. EMBO J. 43:3948–3967. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen F, Peng S, Li C, Yang F, Yi Y, Chen
X, Xu H, Cheng B, Xu Y and Xie X: Nitidine chloride inhibits mTORC1
signaling through ATF4-mediated Sestrin2 induction and targets
IGF2R for lysosomal degradation. Life Sci. 353:1229182024.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Oricchio E, Katanayeva N, Donaldson MC,
Sungalee S, Pasion JP, Béguelin W, Battistello E, Sanghvi VR, Jiang
M, Jiang Y, et al: Genetic and epigenetic inactivation of SESTRIN1
controls mTORC1 and response to EZH2 inhibition in follicular
lymphoma. Sci Transl Med. 9:eaak99692017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chen J, Ou Y, Luo R, Wang J, Wang D, Guan
J, Li Y, Xia P, Chen PR and Liu Y: SAR1B senses leucine levels to
regulate mTORC1 signalling. Nature. 596:281–284. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kim JH, Jung K, Lee C, Song D, Kim K, Yoo
HC, Park SJ, Kang JS, Lee KR, Kim S, et al: Structure-based
modification of pyrazolone derivatives to inhibit mTORC1 by
targeting the leucyl-tRNA synthetase-RagD interaction. Bioorg Chem.
112:1049072021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gai Z, Hu S, He Y, Yan S, Wang R, Gong G
and Zhao J: L-arginine alleviates heat stress-induced mammary gland
injury through modulating CASTOR1-mTORC1 axis mediated
mitochondrial homeostasis. Sci Total Environ. 926:1720172024.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wang J, Shen C, Zhao G, Hanigan MD and Li
M: Dietary protein re-alimentation following restriction improves
protein deposition via changing amino acid metabolism and
transcriptional profiling of muscle tissue in growing beef bulls.
Anim Nutr. 19:117–130. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Jung JW, Kim JE, Kim E and Lee JW: Amino
acid transporters as tetraspanin TM4SF5 binding partners. Exp Mol
Med. 52:7–14. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Jung JW, Macalino SJY, Cui M, Kim JE, Kim
HJ, Song DG, Nam SH, Kim S, Choi S and Lee JW: Transmembrane 4 L
six family member 5 senses arginine for mTORC1 signaling. Cell
Metab. 29:1306–1319.e7. 2019. View Article : Google Scholar
|
|
72
|
Gu X, Orozco JM, Saxton RA, Condon KJ, Liu
GY, Krawczyk PA, Scaria SM, Harper JW, Gygi SP and Sabatini DM:
SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway.
Science. 358:813–818. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kim SH, Choi JH, Wang P, Go CD, Hesketh
GG, Gingras AC, Jafarnejad SM and Sonenberg N: Mitochondrial
Threonyl-tRNA synthetase TARS2 is required for Threonine-sensitive
mTORC1 activation. Mol Cell. 81:398–407.e4. 2021. View Article : Google Scholar
|
|
74
|
Wang D, Wan X, Du X, Zhong Z, Peng J,
Xiong Q, Chai J and Jiang S: Insights into the Interaction of
lysosomal amino acid transporters SLC38A9 and SLC36A1 involved in
mTORC1 signaling in C2C12 Cells. Biomolecules. 11:13142021.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wang S, Tsun ZY, Wolfson RL, Shen K, Wyant
GA, Plovanich ME, Yuan ED, Jones TD, Chantranupong L, Comb W, et
al: Metabolism. Lysosomal amino acid transporter SLC38A9 signals
arginine sufficiency to mTORC1. Science. 347:188–194. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wang X, Zhang T, Li W, Wang H, Yan L,
Zhang X, Zhao L, Wang N and Zhang B: Arginine alleviates
Clostridium perfringens α toxin-induced intestinal injury in vivo
and in vitro via the SLC38A9/mTORC1 pathway. Front Immunol.
15:13570722024. View Article : Google Scholar
|
|
77
|
Dev G, Chawla AS, Gupta S, Bal V, George
A, Rath S and Arimbasseri GA: Differential Regulation of two arms
of mTORC1 pathway Fine-tunes global protein synthesis in resting B
lymphocytes. Int J Mol Sci. 23:160172022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Knight JRP, Alexandrou C, Skalka GL,
Vlahov N, Pennel K, Officer L, Teodosio A, Kanellos G, Gay DM,
May-Wilson S, et al: MNK inhibition sensitizes KRAS-mutant
colorectal cancer to mTORC1 inhibition by reducing eIF4E
phosphorylation and c-MYC expression. Cancer Discov. 11:1228–1247.
2021. View Article : Google Scholar :
|
|
79
|
Savukaitytė A, Gudoitytė G, Bartnykaitė A,
Ugenskienė R and Juozaitytė E: siRNA knockdown of REDD1 facilitates
Aspirin-mediated dephosphorylation of mTORC1 target 4E-BP1 in
MDA-MB-468 human breast cancer cell line. Cancer Manag Res.
13:1123–1133. 2021. View Article : Google Scholar
|
|
80
|
Llanos S and García-Pedrero JM: A new
mechanism of regulation of p21 by the mTORC1/4E-BP1 pathway
predicts clinical outcome of head and neck cancer. Mol Cell Oncol.
3:e11592752016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Amar-Schwartz A, Ben Hur V, Jbara A, Cohen
Y, Barnabas GD, Arbib E, Siegfried Z, Mashahreh B, Hassouna F,
Shilo A, et al: S6K1 phosphorylates Cdk1 and MSH6 to regulate DNA
repair. ELife. 11:e791282022. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Yang L, Miao L, Liang F, Huang H, Teng X,
Li S, Nuriddinov J, Selzer ME and Hu Y: The mTORC1 effectors S6K1
and 4E-BP play different roles in CNS axon regeneration. Nat
Commun. 5:54162014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Jang SK, Kim G, Ahn SH, Hong J, Jin HO and
Park IC: Duloxetine enhances the sensitivity of non-small cell lung
cancer cells to EGFR inhibitors by REDD1-induced mTORC1/S6K1
suppression. Am J Cancer Res. 14:1087–1100. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhang X, Song W, Gao Y, Zhang Y, Zhao Y,
Hao S and Ni T: The role of tumor metabolic reprogramming in tumor
immunity. Int J Mol Sci. 24:174222023. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
He L, Cho S and Blenis J: mTORC1, the
maestro of cell metabolism and growth. Genes Dev. 39:109–131.
2025.
|
|
87
|
Vaidyanathan S, Salmi TM, Sathiqu RM,
McConville MJ, Cox AG and Brown KK: YAP regulates an
SGK1/mTORC1/SREBP-dependent lipogenic program to support
proliferation and tissue growth. Dev Cell. 57:719–731.e8. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Solanki S, Sanchez K, Ponnusamy V, Kota V,
Bell HN, Cho CS, Kowalsky AH, Green M, Lee JH and Shah YM:
Dysregulated amino acid sensing drives colorectal cancer growth and
metabolic reprogramming leading to chemoresistance.
Gastroenterology. 164:376–391.e13. 2023. View Article : Google Scholar
|
|
89
|
Jin C, Zhu M, Ye J, Song Z, Zheng C and
Chen W: Autophagy: Are amino acid signals dependent on the mTORC1
pathway or independent? Curr Issues Mol Biol. 46:8780–8793. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Zhao Z, Liu J, Gao X, Chen Z, Hu Y, Chen
J, Zang W and Xue W: SCYL1-mediated regulation of the mTORC1
signaling pathway inhibits autophagy and promotes gastric cancer
metastasis. J Cancer Res Clin Oncol. 150:4562024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Tan HWS, Sim AYL and Long YC: Glutamine
metabolism regulates autophagy-dependent mTORC1 reactivation during
amino acid starvation. Nat Commun. 8:3382017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ro SH, Xue X, Ramakrishnan SK, Cho CS,
Namkoong S, Jang I, Semple IA, Ho A, Park HW, Shah YM and Lee JH:
Tumor suppressive role of sestrin2 during colitis and colon
carcinogenesis. ELife. 5:e122042016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Byun JK, Choi YK, Kim JH, Jeong JY, Jeon
HJ, Kim MK, Hwang I, Lee SY, Lee YM, Lee IK and Park KG: A positive
feedback loop between sestrin2 and mTORC2 is required for the
survival of Glutamine-depleted lung cancer cells. Cell Rep.
20:586–599. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Shen S, Zhou H, Xiao Z, Zhan S, Tuo Y,
Chen D, Pang X, Wang Y and Wang J: PRMT1 in human neoplasm: Cancer
biology and potential therapeutic target. Cell Commun Signal.
22:1022024. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhou M, Huang Y, Xu P, Li S, Duan C, Lin
X, Bao S, Zou W, Pan J, Liu C and Jin Y: PRMT1 promotes the
Self-renewal of leukemia stem cells by regulating protein
synthesis. Adv Sci (Weinh). 12:e23085862025. View Article : Google Scholar
|
|
96
|
Yin JZ, Keszei AFA, Houliston S, Filandr
F, Beenstock J, Daou S, Kitaygorodsky J, Schriemer DC,
Mazhab-Jafari MT, Gingras AC and Sicheri F: The HisRS-like domain
of GCN2 is a pseudoenzyme that can bind uncharged tRNA. Structure.
32:795–811.e6. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kim Y, Sundrud MS, Zhou C, Edenius M,
Zocco D, Powers K, Zhang M, Mazitschek R, Rao A, Yeo CY, et al:
Aminoacyl-tRNA synthetase inhibition activates a pathway that
branches from the canonical amino acid response in mammalian cells.
Proc Natl Acad Sci USA. 117:8900–8911. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Brüggenthies JB, Fiore A, Russier M,
Bitsina C, Brötzmann J, Kordes S, Menninger S, Wolf A, Conti E,
Eickhoff JE and Murray PJ: A cell-based chemical-genetic screen for
amino acid stress response inhibitors reveals torins reverse stress
kinase GCN2 signaling. J Biol Chem. 298:1026292022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Sannino S, Yates ME, Schurdak ME,
Oesterreich S, Lee AV, Wipf P and Brodsky JL: Unique integrated
stress response sensors regulate cancer cell susceptibility when
Hsp70 activity is compromised. ELife. 10:e649772021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Nelson AT, Cicardi ME, Markandaiah SS, Han
JY, Philp NJ, Welebob E, Haeusler AR, Pasinelli P, Manfredi G,
Kawamata H and Trotti D: Glucose hypometabolism prompts RAN
translation and exacerbates C9orf72-related ALS/FTD phenotypes.
EMBO Rep. 25:2479–2510. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Yuan J, Yu Z, Gao J, Luo K, Shen X, Cui B
and Lu Z: Inhibition of GCN2 alleviates hepatic steatosis and
oxidative stress in obese mice: Involvement of NRF2 regulation.
Redox Biol. 49:1022242022. View Article : Google Scholar :
|
|
102
|
Missiaen R, Anderson NM, Kim LC, Nance B,
Burrows M, Skuli N, Carens M, Riscal R, Steensels A, Li F and Simon
MC: GCN2 inhibition sensitizes arginine-deprived hepatocellular
carcinoma cells to senolytic treatment. Cell Metab.
34:1151–1167.e7. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Stonyte V, Mastrangelopoulou M, Timmer R,
Lindbergsengen L, Vietri M, Campsteijn C and Grallert B: The
GCN2/eIF2αK stress kinase regulates PP1 to ensure mitotic fidelity.
EMBO Rep. 24:e561002023. View Article : Google Scholar
|
|
104
|
Weber SL, Hustedt K, Schnepel N, Visscher
C and Muscher-Banse AS: Modulation of GCN2/eIF2α/ATF4 pathway in
the liver and induction of FGF21 in young goats fed a Protein-
and/or Phosphorus-reduced diet. Int J Mol Sci. 24:71532023.
View Article : Google Scholar
|
|
105
|
Ge MK, Zhang C, Zhang N, He P, Cai HY, Li
S, Wu S, Chu XL, Zhang YX, Ma HM, et al: The
tRNA-GCN2-FBXO22-axis-mediated mTOR ubiquitination senses amino
acid insufficiency. Cell Metab. 35:2216–2230.e8. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Müller MBD, Kasturi P, Jayaraj GG and
Hartl FU: Mechanisms of readthrough mitigation reveal principles of
GCN1-mediated translational quality control. Cell.
186:3227–3244.e20. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bou-Nader C, Gaikwad S, Bahmanjah S, Zhang
F, Hinnebusch AG and Zhang J: Gcn2 structurally mimics and
functionally repurposes the HisRS enzyme for the integrated stress
response. Proc Natl Acad Sci USA. 121:e24096281212024. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ishimura R, Nagy G, Dotu I, Chuang JH and
Ackerman SL: Activation of GCN2 kinase by ribosome stalling links
translation elongation with translation initiation. ELife.
5:e142952016. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Inglis AJ, Masson GR, Shao S, Perisic O,
McLaughlin SH, Hegde RS and Williams RL: Activation of GCN2 by the
ribosomal P-stalk. Proc Natl Acad Sci USA. 116:4946–4954. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Piecyk M, Ferraro-Peyret C, Laville D,
Perros F and Chaveroux C: Novel insights into the GCN2 pathway and
its targeting. Therapeutic value in cancer and lessons from lung
fibrosis development. FEBS J. 291:4867–4889. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Chen C, Xie Y and Qian S: Multifaceted
role of GCN2 in tumor adaptation and therapeutic targeting. Transl
Oncol. 49:1020962024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Nofal M, Wang T, Yang L, Jankowski CSR,
Hsin-Jung Li S, Han S, Parsons L, Frese AN, Gitai Z, Anthony TG, et
al: GCN2 adapts protein synthesis to scavenging-dependent growth.
Cell Syst. 13:158–172.e9. 2022. View Article : Google Scholar :
|
|
113
|
St Paul M, Saibil SD, Kates M, Han S, Lien
SC, Laister RC, Hezaveh K, Kloetgen A, Penny S, Guo T, et al: Ex
vivo activation of the GCN2 pathway metabolically reprograms T
cells, leading to enhanced adoptive cell therapy. Cell Rep Med.
5:1014652024. View Article : Google Scholar
|
|
114
|
Zhao L, Deng L, Zhang Q, Jing X, Ma M, Yi
B, Wen J, Ma C, Tu J, Fu T and Shen J: Autophagy contributes to
sulfonylurea herbicide tolerance via GCN2-independent regulation of
amino acid homeostasis. Autophagy. 14:702–714. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Nakamura A, Nambu T, Ebara S, Hasegawa Y,
Toyoshima K, Tsuchiya Y, Tomita D, Fujimoto J, Kurasawa O, Takahara
C, et al: Inhibition of GCN2 sensitizes ASNS-low cancer cells to
asparaginase by disrupting the amino acid response. Proc Natl Acad
Sci USA. 115:e7776–e7785. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Blagojevic B, Almouhanna F, Poschet G and
Wölfl S: Cell Type-specific metabolic response to amino acid
starvation dictates the role of Sestrin2 in regulation of mTORC1.
Cells. 11:38632022. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Ye J, Palm W, Peng M, King B, Lindsten T,
Li MO, Koumenis C and Thompson CB: GCN2 sustains mTORC1 suppression
upon amino acid deprivation by inducing Sestrin2. Genes Dev.
29:2331–2336. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Averous J, Lambert-Langlais S, Mesclon F,
Carraro V, Parry L, Jousse C, Bruhat A, Maurin AC, Pierre P, Proud
CG and Fafournoux P: GCN2 contributes to mTORC1 inhibition by
leucine deprivation through an ATF4 independent mechanism. Sci Rep.
6:276982016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Carlson KR, Georgiadis MM, Tameire F,
Staschke KA and Wek RC: Activation of Gcn2 by small molecules
designed to be inhibitors. J Biol Chem. 299:1045952023. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Krall AS, Mullen PJ, Surjono F, Momcilovic
M, Schmid EW, Halbrook CJ, Thambundit A, Mittelman SD, Lyssiotis
CA, Shackelford DB, et al: Asparagine couples mitochondrial
respiration to ATF4 activity and tumor growth. Cell Metab.
33:1013–1026.e6. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Kardos GR, Wastyk HC and Robertson GP:
Disruption of proline synthesis in melanoma inhibits protein
production mediated by the GCN2 pathway. Mol Cancer Res.
13:1408–1420. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Vynnytska-Myronovska BO, Kurlishchuk Y,
Chen O, Bobak Y, Dittfeld C, Hüther M, Kunz-Schughart LA and Stasyk
OV: Arginine starvation in colorectal carcinoma cells: Sensing,
impact on translation control and cell cycle distribution. Exp Cell
Res. 341:67–74. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Ren W, Li Y, Xia X, Guo W, Zhai T, Jin Y,
Che Y, Gao H, Duan X, Ma H, et al: Arginine inhibits the malignant
transformation induced by interferon-gamma through the
NF-κB-GCN2/eIF2α signaling pathway in mammary epithelial cells in
vitro and in vivo. Expl Cell Res. 368:236–247. 2018. View Article : Google Scholar
|
|
124
|
Cordova RA, Misra J, Amin PH, Klunk AJ,
Damayanti NP, Carlson KR, Elmendorf AJ, Kim HG, Mirek ET, Elzey BD,
et al: GCN2 eIF2 kinase promotes prostate cancer by maintaining
amino acid homeostasis. ELife. 11:e810832022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Chen C and Zhang J: Enhancing leukemia
treatment: The role of combined therapies based on amino acid
starvation. Cancers (Basel). 16:11712024. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Szczygiel M, Derewenda U, Scheiner S,
Minor W and Derewenda ZS: A structural role for tryptophan in
proteins, and the ubiquitous Trp Cδ1-H...O=C (backbone) hydrogen
bond. Acta Crystallogr D Struct Biol. 80:551–562. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Basson C, Serem JC, Hlophe YN and Bipath
P: The tryptophan-kynurenine pathway in immunomodulation and cancer
metastasis. Cancer Med. 12:18691–18701. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Hanif N and Sari S: Discovery of novel
IDO1/TDO2 dual inhibitors: A consensus Virtual screening approach
with molecular dynamics simulations, and binding free energy
analysis. J Biomol Struct Dyn. 43:6954–6970. 2025. View Article : Google Scholar
|
|
129
|
Thapa K, Khan H, Kaur G, Kumar P and Singh
TG: Therapeutic targeting of angiopoietins in tumor angiogenesis
and cancer development. Biochem Biophys Res Commun. 687:1491302023.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Longchamp A, Mirabella T, Arduini A,
MacArthur MR, Das A, Treviño-Villarreal JH, Hine C, Ben-Sahra I,
Knudsen NH, Brace LE, et al: Amino acid restriction triggers
angiogenesis via GCN2/ATF4 regulation of VEGF and H2S production.
Cell. 173:117–129.e14. 2018. View Article : Google Scholar :
|
|
131
|
Hsu CC, Tseng LM and Lee HC: Role of
mitochondrial dysfunction in cancer progression. Exp Biol Med
(Maywood). 241:1281–1295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Quirós PM, Mottis A and Auwerx J:
Mitonuclear communication in homeostasis and stress. Nat Rev Mol
Cell Biol. 17:213–226. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Liu Q, Zhu J, Abulizi G and Hasim A:
Metabolism and spatial transcription resolved heterogeneity of
glutamine metabolism in cervical carcinoma. BMC Cancer.
24:15042024. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Li J, Chen Y, Yang Y, Yang Y and Wu Z:
High-level L-Gln compromises intestinal amino acid utilization
efficiency and inhibits protein synthesis by GCN2/eIF2α/ATF4
signaling pathway in piglets fed low-crude protein diets. Anim
Nutr. 19:480–487. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Patel R, Alfarsi LH, El-Ansari R, Masisi
BK, Erkan B, Fakroun A, Ellis IO, Rakha EA and Green AR: ATF4 as a
prognostic marker and modulator of glutamine metabolism in
oestrogen Receptor-positive breast cancer. Pathobiology.
91:411–421. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Chen J, Huang X, Zhang S and Zhu X: ATF4
inhibits tumor development and mediates p-GCN2/ASNS upregulation in
colon cancer. Sci Rep. 14:130422024. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Jin HO, Hong SE, Kim JY, Jang SK and Park
IC: Amino acid deprivation induces AKT activation by inducing
GCN2/ATF4/REDD1 axis. Cell Death Dis. 12:11272021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhao C, Guo H, Hou Y, Lei T, Wei D and
Zhao Y: Multiple roles of the stress sensor GCN2 in immune cells.
Int J Mol Sci. 24:42852023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Bartok O, Pataskar A, Nagel R, Laos M,
Goldfarb E, Hayoun D, Levy R, Körner PR, Kreuger IZM, Champagne J,
et al: Anti-tumour immunity induces aberrant peptide presentation
in melanoma. Nature. 590:332–337. 2021. View Article : Google Scholar
|
|
140
|
Halaby MJ, Hezaveh K, Lamorte S, Ciudad
MT, Kloetgen A, MacLeod BL, Guo M, Chakravarthy A, Medina TDS, Ugel
S, et al: GCN2 drives macrophage and MDSC function and
immunosuppression in the tumor microenvironment. Sci Immunol.
4:eaax81892019. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Gauthier-Coles G, Rahimi F, Bröer A and
Bröer S: Inhibition of GCN2 Reveals Synergy with Cell-Cycle
Regulation and Proteostasis. Metabolites. 13:10642023. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Zhang CW, Wang YN and Ge XL: Lenalidomide
use in multiple myeloma (review). Mol Clin Oncol. 20:72024.
View Article : Google Scholar
|
|
143
|
Chattopadhyay N, Berger AJ, Koenig E,
Bannerman B, Garnsey J, Bernard H, Hales P, Maldonado Lopez A, Yang
Y, Donelan J, et al: KRAS genotype correlates with proteasome
inhibitor ixazomib activity in preclinical in vivo models of colon
and Non-small cell lung cancer: Potential role of tumor metabolism.
PLoS One. 10:e01448252015. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Saavedra-García P, Roman-Trufero M,
Al-Sadah HA, Blighe K, López-Jiménez E, Christoforou M, Penfold L,
Capece D, Xiong X, Miao Y, et al: Systems level profiling of
chemotherapy-induced stress resolution in cancer cells reveals
druggable trade-offs. Proc Natl Acad Sci USA. 118:e20182291182021.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Punnasseril JMJ, Auwal A, Gopalan V, Lam
AK and Islam F: Metabolic reprogramming of cancer cells and
therapeutics targeting cancer metabolism. Cancer Med.
14:e712442025. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Darawshi O, Yassin O, Shmuel M, Wek RC,
Mahdizadeh SJ, Eriksson LA, Hatzoglou M and Tirosh B:
Phosphorylation of GCN2 by mTOR confers adaptation to conditions of
hyper-mTOR activation under stress. J Biol Chem. 300:1075752024.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Li Q, Chen J, Liu J, Lin T, Liu X, Zhang
S, Yue X, Zhang X, Zeng X and Ren M: Leucine and arginine enhance
milk fat and milk protein synthesis via the CaSR/Gi/mTORC1 and
CaSR/Gq/mTORC1 pathways. Eur J Nutr. 62:2873–2890. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Wang D, Chu WK, Yam JCS, Pang CP, Leung
YC, Shum ASW and Chan SO: GCN2-SLC7A11 axis coordinates autophagy,
cell cycle and apoptosis and regulates cell growth in
retinoblastoma upon arginine deprivation. Cancer Metab. 12:312024.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Mossmann D, Müller C, Park S, Ryback B,
Colombi M, Ritter N, Weißenberger D, Dazert E, Coto-Llerena M,
Nuciforo S, et al: Arginine reprograms metabolism in liver cancer
via RBM39. Cell. 186:5068–5083.e23. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Carpentier J, Pavlyk I, Mukherjee U, Hall
PE and Szlosarek PW: Arginine deprivation in SCLC: Mechanisms and
perspectives for therapy. Lung Cancer (Auckl). 13:53–66.
2022.PubMed/NCBI
|
|
151
|
Chen T, Xu Y, Yang F, Pan Y, Ji N, Li J,
Zeng X, Chen Q, Jiang L and Shen YQ: Crosstalk of glutamine
metabolism between cancer-associated fibroblasts and cancer cells.
Cell Signal. 133:1118742025. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Kim DH, Kim DJ, Park SJ, Jang WJ and Jeong
CH: Inhibition of GLS1 and ASCT2 synergistically enhances the
anticancer effects in pancreatic cancer cells. J Microbiol
Biotechnol. 35:e24120322025. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Pu X, Wu Y, Long W, Sun X, Yuan X, Wang D,
Wang X and Xu M: The m6A reader IGF2BP2 promotes pancreatic cancer
progression through the m6A-SLC1A5-mTORC1 axis. Cancer Cell Int.
25:1222025. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Ihlamur M, Akgul B, Zengin Y, Korkut ŞV,
Kelleci K and Abamor E: The mTOR signaling pathway and mTOR
inhibitors in cancer: Next-generation inhibitors and approaches.
Curr Mol Med. 24:478–494. 2024. View Article : Google Scholar
|
|
155
|
Marafie SK, Al-Mulla F and Abubaker J:
mTOR: Its critical role in metabolic diseases, cancer, and the
aging process. Int J Mol Sci. 25:61412024. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Hassan B, Akcakanat A, Sangai T, Evans KW,
Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, et al:
Catalytic mTOR inhibitors can overcome intrinsic and acquired
resistance to allosteric mTOR inhibitors. Oncotarget. 5:8544–8557.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Powles T, Wheater M, Din O, Geldart T,
Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Wimalasingham
A, et al: A Randomised phase 2 study of AZD2014 versus everolimus
in patients with VEGF-refractory metastatic clear cell renal
cancer. Eur Urol. 69:450–456. 2016. View Article : Google Scholar
|
|
158
|
Taeb S, Rostamzadeh D, Amini SM, Rahmati
M, Eftekhari M, Safari A and Najafi M: MicroRNAs targeted mTOR as
therapeutic agents to improve radiotherapy outcome. Cancer Cell
Int. 24:2332024. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Cai Y, Xu G, Wu F, Michelini F, Chan C, Qu
X, Selenica P, Ladewig E, Castel P, Cheng Y, et al: Genomic
alterations in PIK3CA-mutated breast cancer result in mTORC1
activation and limit the sensitivity to PI3Kα inhibitors. Cancer
Res. 81:2470–2480. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Jia W, Luo S, Guo H and Kong D:
Development of PI3Kα inhibitors for tumor therapy. J Biomol Struct
Dyn. 41:8587–8604. 2023. View Article : Google Scholar
|
|
161
|
Kearney AL and Vasan N: A new wave of
PI3Kα inhibitors. Cancer Discov. 13:2313–2315. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Watanabe T: Recent advances in treatment
of follicular lymphoma: Efficacy of PI3Kα/δ inhibitor (TQ-B3525).
Signal Transduct Target Ther. 9:1342024. View Article : Google Scholar
|
|
163
|
Heydt Q, Xintaropoulou C, Clear A, Austin
M, Pislariu I, Miraki-Moud F, Cutillas P, Korfi K, Calaminici M,
Cawthorn W, et al: Adipocytes disrupt the translational programme
of acute lymphoblastic leukaemia to favour tumour survival and
persistence. Nat Commun. 12:55072021. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Duan Z, Yang M, Yang J, Wu Z, Zhu Y, Jia
Q, Ma X, Yin Y, Zheng J, Yang J, et al: AGFG1 increases cholesterol
biosynthesis by disrupting intracellular cholesterol homeostasis to
promote PDAC progression. Cancer Lett. 598:2171302024. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Mijit M, Boner M, Cordova RA, Gampala S,
Kpenu E, Klunk AJ, Zhang C, Kelley MR, Staschke KA and Fishel ML:
Activation of the integrated stress response (ISR) pathways in
response to Ref-1 inhibition in human pancreatic cancer and its
tumor microenvironment. Front Med (Lausanne). 10:11461152023.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Drainas AP, Hsu WH, Dallas AE, Poltorack
CD, Kim JW, He A, Coles GL, Baron M, Bassik MC and Sage J: GCN2 is
a determinant of the response to WEE1 kinase inhibition in
small-cell lung cancer. Cell Rep. 43:1146062024. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Wu T, Yu Z, Dai J, Li J, Ning F, Liu X,
Zhu N and Zhang X: JPH203 alleviates peritoneal fibrosis via
inhibition of amino acid-mediated mTORC1 signaling. Biochem Biophys
Res Commun. 734:1506562024. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Bo T, Kobayashi S, Inanami O, Fujii J,
Nakajima O, Ito T and Yasui H: LAT1 inhibitor JPH203 sensitizes
cancer cells to radiation by enhancing radiation-induced cellular
senescence. Transl Oncol. 14:1012122021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Häfliger P, Graff J, Rubin M, Stooss A,
Dettmer MS, Altmann KH, Gertsch J and Charles RP: The LAT1
inhibitor JPH203 reduces growth of thyroid carcinoma in a fully
immunocompetent mouse model. J Exp Clin Cancer Res. 37:2342018.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Okano N, Naruge D, Kawai K, Kobayashi T,
Nagashima F, Endou H and Furuse J: First-in-human phase I study of
JPH203, an L-type amino acid transporter 1 inhibitor, in patients
with advanced solid tumors. Invest New Drugs. 38:1495–1506. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Zhang Z, Liu R, Shuai Y, Huang Y, Jin R,
Wang X and Luo J: ASCT2 (SLC1A5)-dependent glutamine uptake is
involved in the progression of head and neck squamous cell
carcinoma. Br J Cancer. 122:82–93. 2020. View Article : Google Scholar :
|
|
172
|
Chen XY, Chen X, Liang XH, Lu D, Pan RR,
Xiong QY, Liu XX, Lin JY, Zhang LJ, Chen HZ, et al: Yuanhuacine
suppresses head and neck cancer growth by promoting ASCT2
degradation and inhibiting glutamine uptake. Acta Pharmacol Sin.
46:2779–2792. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Barisaac AS, Abu-Zhayia ER and Ayoub N:
Leveraging valine-restriction-induced DNA damage for targeted
cancer therapy. Mol Cell. 85:468–470. 2025. View Article : Google Scholar : PubMed/NCBI
|
